An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update

References

• [cited 2024 May 3]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
   Google Scholar
• NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024 Feb 29. Epub ahead of print. PMID: 38432237. doi:10.1016/S0140-6736(23)02750-2
   Google Scholar
• Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023 Jul;11(7):474–489.
   PubMed Web of Science ®Google Scholar
• Verma M, Das M, Sharma P, et al. Epidemiology of overweight and obesity in Indian adults - a secondary data analysis of the national family health Surveys. Diabetes Metab Syndr. 2021 Jul;15(4):102166.
   PubMed Web of Science ®Google Scholar
• Singhania K, Kalhan M, Choudhary P, et al. Association of menopausal symptoms with overweight and obesity among rural middle aged women in North India: a population based study. J Midlife Health. 2020 Jul;11(3):137–143.
   PubMedGoogle Scholar
• Sridharan K, Cherian KE, Kurian ME, et al. Utility of anthropometric indicators in predicting osteoporosis in ambulant community dwelling rural postmenopausal women from southern India. Trop Doct. 2020 Jul;50(3):228–232.
   PubMed Web of Science ®Google Scholar
• Kapoor N, Lotfaliany M, Sathish T, et al. Prevalence of normal weight obesity and its associated cardio-metabolic risk factors - results from the baseline data of the Kerala Diabetes Prevention Program (KDPP). PLoS One. 2020;15(8):e0237974. doi: 10.1371/journal.pone.0237974
   PubMed Web of Science ®Google Scholar
• Kapoor N, Lotfaliany M, Sathish T, et al. Effect of a peer-led lifestyle intervention on individuals with normal weight obesity: insights from the Kerala Diabetes Prevention Program. Clin Ther. 2020 Aug;42(8):1618–1624.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937–52. doi: 10.1016/S0140-6736(04)17018-9
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kumar P, Srivastava S, et al. Association of anthropometric measures of obesity and physical activity with cardio-vascular diseases among older adults: evidence from a cross-sectional survey, 2017-18. PLoS One. 2021;16(12):e0260148. doi: 10.1371/journal.pone.0260148
   PubMed Web of Science ®Google Scholar
• Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008 Dec;29(7):777–822. Epub 2008 Oct 29. PMID: 18971485; PMCID: PMC5393149. doi: 10.1210/er.2008-0024
   PubMed Web of Science ®Google Scholar
• Pati S, Irfan W, Jameel A, et al. Obesity and cancer: a Current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 2023 Jan 12;15(2):485. doi: 10.3390/cancers15020485
   PubMed Web of Science ®Google Scholar
• Islami F, Goding Sauer A, Gapstur SM, et al. Proportion of cancer cases attributable to excess body weight by US State, 2011-2015. JAMA Oncol. 2019 Mar 1;5(3):384–392. doi: 10.1001/jamaoncol.2018.5639
   PubMed Web of Science ®Google Scholar
• Agarwal S, Melgandi W, Sonkar DR, et al. Epidemiological characteristics of endometrial cancer patients treated at a tertiary health center in national capital territory of India. J Cancer Res Ther. 2023 Jan;19(2):452–456.
   PubMed Web of Science ®Google Scholar
• Singh P, Kapil U, Shukla N, et al. Association of overweight and obesity with breast cancer in India. Indian J Community Med. 2011 Oct;36(4):259–62.
   PubMedGoogle Scholar
• Ramanand SJ, Ghongane BB, Ramanand JB, et al. Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocrinol Metab. 2013 Jan;17(1):138–145. doi: 10.4103/2230-8210.107858
   PubMedGoogle Scholar
• Katole A, Saoji AV. Prevalence of primary infertility and its associated risk factors in urban population of Central India: a community-based cross-sectional study. Indian J Community Med. 2019 Oct;44(4):337–341. doi: 10.4103/ijcm.IJCM_7_19
   PubMed Web of Science ®Google Scholar
• Purkayastha N, Sharma H. Prevalence and potential determinants of primary infertility in India: evidence from Indian demographic health survey. Clin Epidemiol Global Health. 2021 Jan 01;9:162–170. doi: 10.1016/j.cegh.2020.08.008
   Web of Science ®Google Scholar
• Swaminathan G, Swaminathan A, Corsi DJ. Prevalence of gestational diabetes in India by individual socioeconomic, demographic, and clinical factors. JAMA Netw Open. 2020 Nov 2;3(11):e2025074.
   PubMed Web of Science ®Google Scholar
• Pal CP, Singh P, Chaturvedi S, et al. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016 Sep;50(5):518–522.
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Singh R, Rai S. Prevalence and risk factors of gastroesophageal reflux disease in a rural Indian population. Indian J Gastroenterol. 2021 Feb;40(1):56–64. doi: 10.1007/s12664-020-01135-7
   PubMed Web of Science ®Google Scholar
• Bhatia SJ, Reddy DN, Ghoshal UC, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian society of gastroenterology task force. Indian J Gastroenterol. 2011 May;30(3):118–127.
   PubMedGoogle Scholar
• Rameshkumar Vaishya A, Unmesh Shukla Y, Bhise A. Prevalence of obstructive sleep apnea among obese individuals in Ahmedabad – an observational study. Int J Health Sci Res. 2022; 12(9):39–48. doi: 10.52403/ijhsr.20220906
   Google Scholar
• Rajan TM, Menon V. Psychiatric disorders and obesity: a review of association studies. J Postgrad Med. 2017 Jul;63(3):182–190. doi: 10.4103/jpgm.JPGM_712_16
   PubMed Web of Science ®Google Scholar
• Garg R, Saxena SK, Bashir S. Is obesity a risk to depression? A cross-sectional study. Ind Psychiatry J. 2019 Jan;28(1):130–134. doi: 10.4103/ipj.ipj_59_19
   PubMedGoogle Scholar
• Okunogbe A, Nugent R, Spencer G, et al. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Glob Health. 2021 Oct;6(10):e006351.
   PubMed Web of Science ®Google Scholar
• Jiwanmall SA, Kattula D, Nandyal MB, et al. Weight stigma in patients with obesity and its clinical correlates: a perspective from an Indian Bariatric Clinic. Cureus. 2022 Jul;14(7):e26837.
   PubMed Web of Science ®Google Scholar
• Wing RR, Lang W, Wadden TA Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(July (7)):1481–1486. doi: 10.2337/dc10-2415
   PubMed Web of Science ®Google Scholar
• Madhu SV, Nitin K, Sambit D, et al. ESI clinical practice guidelines for the evaluation and management of obesity in India. Indian J Endocrinol Metab. 2022 Jul;26(4):295–318. doi: 10.4103/2230-8210.356236
   PubMedGoogle Scholar
• Saboo B, Phatak S, Jethwani P, et al. Intervention of a personalized low-carbohydrate diet to reduce HbA1c level and weight in patients with type 2 diabetes using seed-based flour as replacement for high-carbohydrate flour and foods. J Diabetol. 2021 Apr;12(2):196–200.
   Google Scholar
• Bhardwaj S, Misra A, Gulati S, et al. A randomized controlled trial to evaluate the effects of high protein complete (lActo) VEgetaRian (PACER) diet in non-diabetic obese Asian Indians in North India. Heliyon. 2017 Dec;3(12):e00472.
   PubMedGoogle Scholar
• Mancini JG, Filion KB, Atallah R, et al. Systematic review of the mediterranean diet for long-term weight loss. Am J Med. 2016 Apr;129(4):407–415.e4. Epub 2015 Dec 22. PMID: 26721635. doi: 10.1016/j.amjmed.2015.11.028
   PubMed Web of Science ®Google Scholar
• Astrup A, Bügel S Micronutrient deficiency in the aetiology of obesity. Int J Obes. 34, 947–948 (2010). doi: 10.1038/ijo.2010.81. 6
   Web of Science ®Google Scholar
• Salis S, Shefa S, Sharma N, et al. Effects of intermittent fasting on weight loss in Asian Indian adults with obesity. J Assoc Physicians India. 2022 Sep;70(9):11–12.
   Google Scholar
• Patikorn C, Roubal K, Veettil SK, et al. Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials. JAMA Netw Open. 2021;4(12):e2139558. doi: 10.1001/jamanetworkopen.2021.39558
   PubMed Web of Science ®Google Scholar
• Deshpande N, Mamata AH, Parmaj R, et al. The immediate impact of a balanced, very low-calorie diet on the metabolic health of Indian subjects - a prospective longitudinal study. Clin Epidemiol Global Health. 2023 Nov 01;24:101397.
   Web of Science ®Google Scholar
• Gupta Jain S, Puri S, Misra A, et al. Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double -blind control trial. Lipids Health Dis. 2017 Jun 12;16(1):113. doi: 10.1186/s12944-017-0504-8
   PubMedGoogle Scholar
• Bhatt SP, Misra A, Pandey RM, et al. Vitamin D supplementation in overweight/obese Asian Indian women with prediabetes reduces glycemic measures and truncal subcutaneous fat: a 78 weeks randomized placebo-controlled trial (PREVENT-WIN trial). Sci Rep. 2020 Jan 14;10(1):220. doi: 10.1038/s41598-019-56904-y
   PubMed Web of Science ®Google Scholar
• Bellicha A, van Baak MA, Battista F, et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: an overview of 12 systematic reviews and 149 studies. Obes Rev. 2021 Jul;Suppl 22(Suppl S4):e13256. Epub 2021 May 6. PMID: 33955140; PMCID: PMC8365736. doi: 10.1111/obr.13256
   Google Scholar
• Battista F, Ermolao A, van Baak MA, et al. Effect of exercise on cardiometabolic health of adults with overweight or obesity: focus on blood pressure, insulin resistance, and intrahepatic fat—A systematic review and meta-analysis. Obes Rev. 2021 Jul;Suppl 22(Suppl S4):e13269.
   Google Scholar
• Lopez P, Taaffe DR, Galvão DA, et al. Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: a systematic review and meta-analysis. Obes Rev. 2022 May;23(5):e13428.
   PubMed Web of Science ®Google Scholar
• Beaulieu K, Blundell JE, van Baak MA, et al. Effect of exercise training interventions on energy intake and appetite control in adults with overweight or obesity: a systematic review and meta-analysis. Obes Rev. 2021 Jul;Suppl 22(Suppl S4):e13251.
   Google Scholar
• Carraça EV, Encantado J, Battista F, et al. Effect of exercise training on psychological outcomes in adults with overweight or obesity: a systematic review and meta-analysis. Obes Rev. 2021 Jul;Suppl 22(Suppl S4):e13261.
   Google Scholar
• DiPietro L, Buchner DM, Marquez DX, et al. New scientific basis for the 2018 U.S. Physical activity guidelines. J Sport Health Sci. 2019 May;8(3):197–200. doi: 10.1016/j.jshs.2019.03.007
   PubMed Web of Science ®Google Scholar
• Sturgiss E, van Weel C. The 5 as framework for obesity management: do we need a more intricate model? Can Fam Physician. 2017 Jul;63(7):506–508.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20;281(3):235–242. Erratum in: JAMA 1999 Apr 7;281(13):1174. PMID: 9918478. doi: 10.1001/jama.281.3.235
   PubMed Web of Science ®Google Scholar
• Apovian CM. Naltrexone/Bupropion for the treatment of obesity and obesity with type 2 diabetes. Future Cardiol. 2016 Mar;12(2):129–38. Epub 2015 Dec 18. PMID: 26679384. doi: 10.2217/fca.15.79
   PubMedGoogle Scholar
• Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013 Nov;21(11):2163–2171. Epub 2013 Oct 17. PMID: 24136928. doi: 10.1002/oby.20584
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020;13(1):53–64. doi: 10.1080/17512433.2020.1698291
   PubMed Web of Science ®Google Scholar
• Grossman S Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide. Pharmacotherapy. 29(12 Pt 2), 25s–32s (2009). doi: 10.1592/phco.29.pt2.25S
   PubMed Web of Science ®Google Scholar
• Kalra S, Bhattacharya S, Kapoor N. Contemporary classification of glucagon-like peptide 1 receptor agonists (GLP1RAs). Diabetes Ther. 2021;12(8):2133–2147. doi:10.1007/s13300-021-01113-y
   PubMed Web of Science ®Google Scholar
• Buse JB, Bain SC, Mann JFE, et al. Cardiovascular risk reduction with liraglutide: an Exploratory Mediation analysis of the LEADER trial. Diabetes Care. 2020;43(7):1546–1552. doi: 10.2337/dc19-2251
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diab Obes Metab. 2018;20(3):734–739. doi:10.1111/dom.13125
   PubMed Web of Science ®Google Scholar
• Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017;40(7):839–848. doi:10.2337/dc16-2684
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699. doi: 10.1001/jama.2015.9676
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. doi: 10.1021/acs.jmedchem.5b00726
   PubMed Web of Science ®Google Scholar
• Nauck MA, Petrie JR, Sesti G, et al. Study 1821 investigators. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016 Feb;39(2):231–41. Epub 2015 Sep 10. PMID: 26358288. doi: 10.2337/dc15-0165.
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. doi: 10.1016/S2213-8587(17)30013-X
   PubMed Web of Science ®Google Scholar
• Goldenberg RM, Steen O. Semaglutide: review and place in therapy for adults with type 2 diabetes. Can J Diabetes. 2019 Mar;43(2):136–145. doi: 10.1016/j.jcjd.2018.05.008
   PubMed Web of Science ®Google Scholar
• Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 28(6), 1050–1061 (2020). doi: 10.1002/oby.22794
   PubMed Web of Science ®Google Scholar
• Adler AI. The STEP 1 trial for weight loss: a step change in treating obesity? Nat Med. 2021;27(4):589–590. doi:10.1038/s41591-021-01319-4
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984. doi: 10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413. doi: 10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi: 10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083–2091. doi: 10.1038/s41591-022-02026-4
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193–206. doi: 10.1016/S2213-8587(22)00008-0
   PubMed Web of Science ®Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. Pioneer 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732. doi: 10.2337/dc19-0749
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281. doi: 10.2337/dc19-0883
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral sem-aglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466e80. doi: 10.1001/jama.2019.2942
   Web of Science ®Google Scholar
• Pratley RE, Amod A, Tetens Hoff S, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39e50. doi: 10.1016/S0140-6736(19)31271-1
   Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–527. doi: 10.1016/S2213-8587(19)30192-5
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019 Aug 29;381(9):841–851. doi: 10.1056/NEJMoa1901118
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528e39. doi: 10.1016/S2213-8587(19)30194-9
   Web of Science ®Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety and tolerability of oral semaglutide versus placebo added to insulin ± metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–2271. doi: 10.2337/dc19-0898
   PubMed Web of Science ®Google Scholar
• Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, multicentre trial. Lancet Diabetes Endocrinol. 2020;8(5):377–391. doi: 10.1016/S2213-8587(20)30075-9
   PubMed Web of Science ®Google Scholar
• Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endo-Crinol. 2020;8(5):392–406. doi: 10.1016/S2213-8587(20)30074-7
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh R, Misra A. Oral semaglutide in type 2 diabetes mellitus: comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes Metab Syndr. 2022 Mar;16(3):102436. doi: 10.1016/j.dsx.2022.102436
   PubMed Web of Science ®Google Scholar
• Singh AK Gauging the antiobesity potential of oral semaglutide in type 2 diabetes in the Indian context. Indian J Clin Pract. 2023; 33(11): 8–12.
   Google Scholar
• Aroda VR, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402(10403):693–704. doi: 10.1016/S0140-6736(23)01127-3
   PubMed Web of Science ®Google Scholar
• Knop FK, Aroda VR, Do Vale RD, et al. OASIS 1 investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705–719. doi: 10.1016/S0140-6736(23)01185-6
   PubMed Web of Science ®Google Scholar
• Patel H, Khunti K, Rodbard HW, et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diab Obes Metab. 2024; 26(2):473–481. doi: 10.1111/dom.15333
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 investigators. Tirzepatide Once weekly for the treatment of obesity. N Engl J Med. 2022 Jul 21;387(3):205–216. doi: 10.1056/NEJMoa2206038
   PubMed Web of Science ®Google Scholar
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626. doi: 10.1016/S0140-6736(23)01200-X
   PubMed Web of Science ®Google Scholar
• Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909–2918. doi: 10.1038/s41591-023-02597-w
   PubMed Web of Science ®Google Scholar
• Karakasis P, Patoulias D, Pamporis K, et al. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2023;149:155710. doi: 10.1016/j.metabol.2023.155710
   PubMed Web of Science ®Google Scholar
• Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720–730. doi: 10.1016/S0140-6736(23)01163-7
   PubMed Web of Science ®Google Scholar
• Klein T, Augustin R, Hennige AM. Perspectives in weight control in diabetes – survodutide. Diabet Res Clin Pract. 2024;207:110779. doi: 10.1016/j.diabres.2023.110779
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Kaplan LM, FríFríAs JP, et al. Retatrutide phase 2 obesity trial investigators. triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial. N Engl J Med. 2023 Aug 10;389(6):514–526. doi: 10.1056/NEJMoa2301972
   PubMed Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020 Feb;75(2):235–251. doi: 10.1037/amp0000517
   PubMed Web of Science ®Google Scholar
• Bhasker AG, Prasad A, Raj PP, et al. OSSI (obesity and metabolic surgery society of India) guidelines for patient and procedure selection for bariatric and metabolic surgery. Obes Surg. 2020 Jun;30(6):2362–2368. doi: 10.1007/s11695-020-04497-1
   PubMed Web of Science ®Google Scholar
• Kular KS, Manchanda N, Rutledge R. Analysis of the five-year outcomes of sleeve gastrectomy and mini gastric bypass: a report from the Indian sub-continent. Obes Surg. 2014 Oct;24(10):1724–8. doi: 10.1007/s11695-014-1264-4
   PubMed Web of Science ®Google Scholar
• Kular KS, Manchanda N, Cheema GK. Seven years of mini-gastric bypass in type II diabetes patients with a Body Mass Index < 35 kg/m2. Obes Surg. 2016 Jul;26(7):1457–1462. doi: 10.1007/s11695-015-1941-y
   PubMed Web of Science ®Google Scholar
• Jammu GS, Sharma R. A 7-year clinical audit of 1107 cases comparing sleeve gastrectomy, roux-en-y gastric bypass, and mini-gastric bypass, to determine an effective and safe bariatric and metabolic procedure. Obes Surg. 2016 May;26(5):926–932. doi: 10.1007/s11695-015-1869-2
   PubMed Web of Science ®Google Scholar
• Singla V, Aggarwal S, Garg H, et al. Outcomes in super obese patients undergoing laparoscopic sleeve Gastrectomy. J Laparoendosc Adv Surg Tech A. 2018 Mar;28(3):256–262.
   PubMed Web of Science ®Google Scholar
• Arumugaswamy P, Singla V, Aggarwal S, et al. (2022). Medium-term outcomes after roux-en-Y-Gastric bypass: experience from a tertiary healthcare center from India. J Bariatr Surg. 1(1):16. doi: 10.4103/jbs.jbs_2_22
   Google Scholar
• Misra S, Bhattacharya S, Saravana Kumar S, et al. Long-term outcomes of laparoscopic sleeve gastrectomy from the Indian subcontinent. Obes Surg. 2019 Dec;29(12):4043–4055.
   PubMed Web of Science ®Google Scholar
• Bhandari M, Nautiyal HK, Kosta S, et al. Comparison of one-anastomosis gastric bypass and roux-en-Y gastric bypass for treatment of obesity: a 5-year study. Surg Obes Relat Dis. 2019 Dec;15(12):2038–2044.
   PubMed Web of Science ®Google Scholar
• Jain M, Tantia O, Goyal G, et al. LSG vs MGB-OAGB: 5-year follow-up data and comparative outcome of the two procedures over long term—results of a randomised control trial. Obes Surg. 2021 Mar;31(3):1223–1232.
   PubMed Web of Science ®Google Scholar
• Jain M, Tantia O, Goyal G, et al. LSG vs MGB-OAGB: 5-year follow-up data and comparative outcome of the two procedures over long term-results of a randomised control trial. Obes Surg. 2021 Mar;31(3):1223–1232. doi: 10.1007/s11695-020-05119-6
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. On behalf of the SELECT trial investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 Nov 11;389(24):2221–2232. [Epub ahead of print]. doi:10.1056/NEJMoa2307563
   PubMed Web of Science ®Google Scholar
• Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF trial committees and investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023 Sep 21;389(12):1069–1084. doi: 10.1056/NEJMoa2306963
   PubMedGoogle Scholar